Introduction
There is a continuing need for antiarrhythmic drugs that are both safe and eective. Drugs classed by the VaughanWilliam's scheme as Class III prolong cardiac action potentials and, therefore, the QT interval of the ECG. It is clear that this class of drugs can have useful antiarrhythmic actions; however, the proarrhythmic actions of such drugs severely limit their utility. For example, ibutilide (Stambler et al., 1997; Oral et al., 1999) , dofetilide (Frost et al., 1997; Torp-Pedersen et al., 1999) and sotalol (Kehoe et al., 1990) are associated with a signi®cant risk of torsades de pointes. In contrast, the risk of torsades de pointes with amiodarone is regarded as being low despite its Class III pro®le (Connolly, 1999) . Unfortunately, pulmonary toxicity limits the use of this drug to high-risk patients. Consequently, there is a continuing need for antiarrhythmic drugs.
Tedisamil is an experimental bradycardic agent being developed for the treatment of angina pectoris (Fox et al., 2000) . The drug prolongs cardiac action potentials and the QT interval of the ECG in experimental animals (Beatch et al., 1991; Tsuchihashi & Curtis, 1991; Rees et al., 1993; Wallace et al., 1995; Chi et al., 1996) and in man (Bargheer et al., 1994; Fox et al., 2000) . Tedisamil brings about these eects via blockade of several cardiac ion currents. These include the delayed recti®er K + current (Dukes & Morad, 1989; Dukes et al., 1990) , transient outward current (Dukes & Morad, 1989; Dukes et al., 1990) , the ATP-dependent K + current (Bray & Quast, 1992) as well as the fast inward sodium current (Beatch et al., 1991; Nemeth et al., 1996) and the cyclic AMP-activated Cl 7 current (Faivre et al., 1998) . Experimental studies have demonstrated that tedisamil has antiarrhythmic actions in vitro (Tsuchihashi & Curtis, 1991; Chi et al., 1996) and in vivo against arrhythmias arising from the atrium (Fischbach et al., 1999) and ventricle (Beatch et al., 1991; Friedrichs et al., 1996; .
Despite its demonstrated antiarrhythmic eectiveness, it is not clear if tedisamil carries with it a similar risk of torsades de pointes to that observed with Class III antiarrhythmic drugs. The aim of the present study was to examine the actions of tedisamil under conditions where torsades de pointes might be expected to occur (i.e., bradycardia and low [K and proarrhythmic actions of tedisamil were compared to dofetilide. Dofetilide is known to prolong the QT interval of the ECG and precipitate torsades de pointes in experimental animals (Buchanan et al., 1993; Bril et al., 1996) and man (Frost et al., 1997; Torp-Pedersen et al., 1999) .
Methods

Guidelines for animal research
The procedures used in this study were in accordance with the guidelines of the University of Michigan Committee on the Use and Care of Animals. Veterinary care was provided by the University of Michigan Unit for Laboratory Animal Medicine. The University of Michigan is accredited by the American Association of Accreditation of Laboratory Animals Health Care, and the animal care use program conforms to the standards in The Guide for the Care and Use of Laboratory Animals, Department of Health, Education, and Welfare Publication Number (National Institute of Health) 86-23.
General preparation
Male, New Zealand White rabbits (2 ± 3 kg), were stunned by cervical dislocation. The heart was rapidly removed and mounted on a Langendor apparatus. Hearts were perfused with a modi®ed Krebs-Henseleit buer at a constant¯ow of 20 ± 30 ml min 71 such that the coronary perfusion pressure was 50 ± 70 mmHg. The composition of the buer (in mM) was: CaCl 2 1.8, KCl 2.8, KH 2 PO 4 1.2, MgSO 4 0.83, NaCl 118, NaHCO 3 24.88, Na pyruvate 2 and glucose 5.55. The ®nal [K + ] was 4 mM. The buer was bubbled continuously with 95% O 2 /5% CO 2 . The heart was maintained at a constant temperature of 378C using a circulating water bath. An incision was made in the right atrium and the AV node was ablated using forceps. This procedure produced rapid and irreversible AV block and resulted in a low ventricular rate. Pacing leads were inserted into the intraventricular septum and, in the event that heart rate fell below 50 beats min
71
, pacing was initiated at this rate. The average resulting ventricular rate was 50+2 beats min
. An incision was made in the left atrium to allow insertion of a temperature probe and a balloon into the left ventricle. The intraventricular balloon was ®lled with saline to give an end diastolic pressure of 5 mmHg. A volume conducted ECG was recorded as described by Zabel et al. (1997) . This permitted simulated leads V1, V3, V5 and lead II to be recorded simultaneously. The ECG leads, coronary perfusion pressure and left ventricular pressure were monitored using Grass Instruments data acquisition hardware (Models 15AX54 and 15AX12, Quincy, MA, U.S.A.) and Polyview software (version 2.1, Grass Instruments, Quincy, MA, U.S.A.). Hearts were allowed 20 min to equilibrate before starting the experiment.
Experimental protocol for concentration-response studies
The protocol was adapted from that described by Johna et al. (1998) . Hearts were monitored for 5 min before starting an infusion of vehicle control (0.2% dimethylsulphoxide dissolved in buer) into a sidearm on the perfusion apparatus. The infusion rate was 20 ± 30 ml h 71 (i.e., 1/ 60th of the coronary¯ow rate). After 20 min, the perfusate was switched to a low potassium buer ([K + ] 3 mM) for 5 min. Thereafter, the heart was perfused with normal buer ([K + ]4 mM) for 5 min. To assess rate-dependent changes in the QT interval, hearts were paced at 80, 120 and 240 beats min 71 for 1 min, a time sucient to account for the eects of restitution on the QT interval. In the event that the pacing protocol was interrupted by the occurrence of tachyarrhythmias, the pacing duration was extended such that each heart was paced at a constant rate for at least 1 min. QT intervals were also measured during perfusion with 3 and 4 mM [K + ] buer at a pacing rate of 50 beats min 71 or during spontaneous junctional rhythm (depending on which rate was greater).
Hearts then were assigned to receive either continued infusion with vehicle control, dofetilide at successively increasing concentrations of 3 and 30 nM, or tedisamil at concentrations of 0.3 mM, followed by 3 mM. Drug solutions were made up at 60 times the desired concentration and infused at 1/60th of the coronary¯ow rate into a sidearm on the perfusion apparatus. The protocol described above was repeated at each concentration of the drug. Thus, each heart was treated with two test concentrations of vehicle control, dofetilide or tedisamil.
Experimental protocol for heart rate response studies
In a separate group of hearts, the rate-dependent and pausedependent proarrhythmic actions of dofetilide and tedisamil were explored. Rabbit isolated hearts were set up as described above. Perfusate [K + ] was maintained at 4 mM throughout this protocol. Hearts were paced for 20 min at each of 50, 100, 200 and 50 beats min
71
, successively. Pauses were inserted in the basic pacing train at various times to assess the occurrence of pause-dependent torsades de pointes (see below for de®nition). Every 10 min, three pauses were inserted in the basic train. In addition, three pauses were inserted within the ®rst minute at each new pacing rate. The duration of the pause varied between 2 ± 6 s, depending on the rate of the spontaneously junctional rhythm of the heart. In this way, the spontaneous occurrence of torsades de pointes could be assessed during the basic pacing protocol and the occurrence of pause-dependent torsades de pointes could be assessed by introducing a pause in cardiac activity. Hearts were assigned to treatment with vehicle control, 30 nM dofetilide, or 3 mM tedisamil. Infusions were carried out as described above. QT intervals were measured 19 min after commencing pacing at each rate (i.e., just before introducing the ®nal pause in cardiac activity at each pacing rate).
Assessment of serum [K + ] in conscious rabbits
A blood sample was obtained from the marginal ear vein of 35 rabbits before starting the protocol. Blood samples (1 ml) were heparinised and spun at 40006g for 10 min. The [K + ] of the plasma was measured using a potassium selective electrode (Model 16.40, Instrumentation Laboratory, Lexington, MA, U.S.A.).
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Drugs
Tedisamil was obtained from Kali-Chemi (Hanover, Germany) and dofetilide was obtained from P®zer (Sandwich, U.K.). The test concentrations of tedisamil were selected on the basis of previous studies in our laboratory Friedrichs et al., 1998) , as well as others (Tsuchihashi & Curtis, 1991) , which demonstrated that tedisamil had antiarrhythmic actions over this concentration range (0.3 ± 3 mM) in vitro and in vivo. The lowest concentration of dofetilide (3 nM) was selected on the basis of a literature report that demonstrated the antiarrhythmic activity of this drug in man (Echt et al., 1995) . The highest concentration of dofetilide was intended to be supra-maximal, such that a high incidence of torsades de pointes could be observed (i.e., 30 nM dofetilide served as a positive control).
Definition of end points
The QT interval was measured from the Q wave, or the onset of the R wave if a Q wave was not present, to the point where a tangent drawn to the steepest portion of the T wave crossed the isoelectric line. Other less conventional measures of repolarization time were obtained from the ECG. The QTa interval was measured from the Q wave, or the onset of the R wave if a Q wave was not present, to the peak of the T wave. The interval between the peak and the end of the T wave (QTa-e) was measured as an indicator of the homogeneity of the repolarization process (Antzelevitch et al., 1999) . All of the above noted measures were made from lead II of the ECG from three successive beats.
For the purposes of this study, torsades de pointes was de®ned as a`polymorphic ventricular tachycardia characterized by an onset with abnormal QT-prolongation and/or abnormal TU complexes, the electrocardiographic con®gura-tion of a progressively changing ventricular axis, and spontaneous termination with the exception of rare degeneration into ventricular ®brillation', as recently described by Eckardt et al. (1998) . A minimum of four beats was required to diagnose torsades de pointes. As the ECG morphology of torsades de pointes is known to depend on the lead considered, monitoring multiple ECG leads was necessary to ensure accurate diagnosis. In the heart rate response studies, pause-dependent torsades de pointes was said to occur if torsades de pointes occurred within 1 min after a pause in cardiac activity.
Statistics
All data are summarized as the mean+s.e.mean, n=4 ± 7 in each group. At the higher test concentration of each drug and at low pacing rates, QT intervals could not be measured due to the occurrence of premature ventricular beats and torsades de pointes. Repeated measures analysis of variance (ANOVA) was used to test for statistical signi®cance and a Tukey test was used to detect dierences between groups. All statistical tests were two tailed and a value of P50.05 was considered statistically signi®cant. The incidence of torsades de pointes was analysed using a Chi Square analysis.
Results
QT prolonging and proarrhythmic actions of dofetilide and tedisamil
The QT interval was longer at lower pacing rates (P50.05) before drug treatment in all groups (Figure 1 ). Both dofetilide and tedisamil exacerbated this eect and QT intervals were prolonged in a concentration-and reverse rate-dependent fashion relative to vehicle control (Figure 1) . The QTa-e interval did not vary with heart rate in vehicle treated hearts but was prolonged in a concentration-and reverse rate-dependent fashion by both dofetilide and tedisamil (Figure 2 QT prolonging and proarrhythmic actions of dofetilide and tedisamil; effect of heart rate The QT interval exhibited reverse-rate dependent properties such that QT intervals were longer at low pacing rates (P50.05, Figure 5 ). Both dofetilide and tedisamil exacerbated this phenomenon and QT intervals were prolonged in a reverse rate-dependent fashion ( Figure 5 ). The QTa-e interval was prolonged only at a pacing rate of 50 beats min 71 , whereas the QT interval was prolonged at all pacing rates relative to vehicle control ( Figure 5 ). In this way the QTa-e interval was more speci®cally associated with the occurrence of torsades de pointes (r=0.91, P50.01).
In parallel to the reverse rate-dependent actions of both drugs on the QT interval, the incidence of torsades de pointes was greater at lower pacing rates (Table 2) . At a pacing rate of 50 beats min 71 all hearts treated with either 3 mM tedisamil or 30 nM dofetilide exhibited torsades de pointes. The ®rst time hearts were paced at 50 beats min 71 torsades de pointes was observed in 4/5 hearts in each drug-treated group. During pacing at 50 beats min 71 the second time, torsades de pointes was observed in the one heart in each drug-treated group in which it was not observed during the ®rst pacing episode at this rate. Thus, the overall incidence of torsades de pointes in drug-treated hearts was 5/5 (P50.05 vs vehicle control).
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Tedisamil-induced torsades de pointes T.D. Barrett et alOnce torsades de pointes occurred spontaneously it could commonly be provoked by a pause in cardiac activity and, in addition, torsades de pointes could be provoked after a pause in cardiac activity at pacing rates where it did not occur spontaneously. Torsades de pointes was observed in 1/5 hearts treated with 30 nM dofetilide and 2/5 hearts treated with 3 mM tedisamil when hearts were paced at 200 beats min 71 (Table 2, Figure 6 ). These pause-dependent events occurred following a stepwise increase in the pacing rate from 100 to 200 beats min
71
. Spontaneous torsades de pointes was Figure 2 The eect of vehicle control (top), dofetilide (middle) and tedisamil (bottom) on the QTa-e interval in rabbit isolated hearts paced at 80, 120 and 240 beats min
. Each point represents the mean+s.e.mean, n=5 ± 7. The QTa-e interval was measured from lead II. The * denotes statistical signi®cance vs vehicle control at P50.05 (repeated measures ANOVA followed by a Tukey test for dierences). . Each point represents the mean+s.e.mean, n=5 ± 7. The QT interval was measured from lead II. The * denotes statistical signi®cance vs vehicle control at P50.05 (repeated measures ANOVA followed by Tukey test). The # denotes statistical signi®cance from the lower concentration of the same agent.
British Journal of Pharmacology vol 132 (7) Tedisamil-induced torsades de pointes T.D. Barrett et alnot observed at a pacing rate of 200 beats min 71 nor could it be precipitated by a pause in cardiac activity after pacing for 10 min at this rate. The proarrhythmic actions of dofetilide and tedisamil were re-established upon reducing the pacing rate to 50 beats min 71 . Torsades de pointes was not observed in vehicle controls and ventricular ®brillation was not observed in any group. ] in rabbits averaged 4.2+0.1 mM (n=35, range 2.7 ± 6.6 mM).
Serum potassium concentration in conscious rabbits
Discussion
The QT prolonging actions of dofetilide and tedisamil were associated with a similar risk of torsades de pointes. Both the QT prolongation and the proarrhythmic actions of dofetilide and tedisamil were concentration-and reverse rate-dependent. Thus, there was a high incidence of torsades de pointes in hearts treated with either 30 nM dofetilide or 3 mM tedisamil under conditions of bradycardia. Tedisamil's pro®le might be particularly insidious as this drug has bradycardic actions and could therefore precipitate the very conditions under which its proarrhythmic actions are manifested. The data also suggest that the proarrhythmic actions of dofetilide were exacerbated by perfusion with a low [K + ] buer. The concentrations tested in the present study have been demonstrated to prolong cardiac action potentials, prolong the QT interval of the ECG and have antiarrhythmic actions in vitro and in vivo (Beatch et al., 1991; Tsuchihashi & Curtis, 1991; Chi et al., 1996; Wallace et al., 1995; Friedrichs et al., 1996; . Our previous studies in the rabbit isolated heart preparation demonstrated the anti®brillatory eects of tedisamil at a concentration of 3 mM . Similarly, a concentration of *0.6 mM has been documented to be eective in our canine sudden death model (Friedrichs et al., 1998) . The concentrations tested in the present study are therefore directly relevant to the observed antiarrhythmic actions of tedisamil and the use of this agent to prevent or revert cardiac arrhythmias is likely to be associated with a risk of torsades de pointes in man. The doses used to treat angina pectoris in man are somewhat lower than those demonstrated to have antiarrhythmic actions in animal models. Despite the lower dose of tedisamil, the QTc interval Figure 3 The eect of vehicle control, dofetilide and tedisamil on the QT interval in rabbit isolated hearts during perfusion with 3 or 4 mM [K + ]. Mean QT intervals+s.e.mean, n=4 ± 7 during perfusion with vehicle control, dofetilide (C1=3 nM and C2=30 nM) or tedisamil (C1=0.3 mM and C2=3 mM). PD denotes pre-drug values. QT intervals were measured from lead II. The group mean ventricular rate was 50+2 beats min
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. The * denotes statistical signi®cance vs vehicle control at P50.05 (repeated measures ANOVA followed by a Tukey test for dierences). Results are presented as the group incidence of torsades de pointes. The overall incidence summarizes the occurrence of torsades de pointes during both observation periods. For vehicle control, data are summarized for the entire duration of the experiment in a single column. Statistical signi®cance vs vehicle control was determined using a Chi Square test at a signi®cance level of P50.05.
British Journal of Pharmacology vol 132 (7) Tedisamil-induced torsades de pointes T.D. Barrett et alwas prolonged in clinical trials (Bargheer et al., 1994; Fox et al., 2000) . If prolongation of the QTc interval is taken as a valid measure of the risk of torsades de pointes, then the data suggest that there is a risk of torsades de pointes with tedisamil at doses used to treat angina pectoris.
It is noteworthy that the QTc interval was not prolonged at eective doses (3 mg kg 71 BID p.o.) in our canine sudden death model (Friedrichs et al., 1998) . Torsades de pointes also was not observed in this study. Torsades de pointes also was not observed in our previous in vitro study with tedisamil, despite perfusion of rabbit isolated hearts with a low [K + ] buer (2.5 mM, Chi et al., 1996) . In the latter study, hearts were paced faster than their intrinsic sinus rate. One possible explanation for the apparently incongruent observations is that the proarrhythmic actions of tedisamil are bradycardia dependent (as demonstrated in the present study).
The QT prolonging actions of dofetilide and tedisamil were reverse rate-dependent in keeping with previous observations (Sanguinetti & Jurkiewicz, 1990) . Dofetilide is a potent and selective blocker of the rapidly activating component of the delayed recti®er K + current (I Kr ). Reverse rate-dependent Figure 5 The eects of vehicle control, dofetilide and tedisamil on the QT interval (top) and QTa-e interval (bottom) in rabbit isolated hearts paced at 50, 100, 200 and 50 beats min
. Each point represents the mean+s.e.mean, n=4 ± 5. Both intervals were measured from lead II. The * denotes statistical signi®cance vs vehicle control at P50.05 (repeated measures ANOVA followed by a Tukey test for dierences). Table 2 The eect of heart rate on the incidence of dofetilide and tedisamil-induced torsades de pointes in the rabbit isolated heart ] was 4 mM. Note the presence of AV block, which is characterized by the dissociation between P waves and the QRS complex.
British Journal of Pharmacology vol 132 (7) Tedisamil-induced torsades de pointes T.D. Barrett et alaction potential and QT interval prolongation are the hallmarks of drugs with this pro®le (Hondeghem & Snyders, 1990) . The similarity in the actions of dofetilide and tedisamil suggest that tedisamil's QT prolonging and proarrhythmic actions are mediated by blockade of I Kr . While this might explain the observed eects, it is by no means certain. As noted earlier, tedisamil is known to block a number of cardiac ion currents, any of which might contribute to the observed proarrhythmic eects.
The proarrhythmic actions of dofetilide tended to be exacerbated by perfusion with low [K + ] buer (3 vs 4 mM). Low [K + ] concentrations are known to potentiate the blockade of I Kr produced by dofetilide (Yang & Roden, 1996; Du et al., 1997) . In keeping with this, torsades de pointes occurred in two hearts treated with 30 nM dofetilide during perfusion with 3 mM [K + ] in which torsades de pointes did not occur during perfusion with 4 mM [K + ]. The QTa-e interval was measured in an attempt to assess drug-induced changes in T wave morphology and to relate these changes to the occurrence of torsades de pointes. It has been suggested that changes in T wave morphology and/or the appearance of a U wave may be more predictive of torsades de pointes than QT (or QTc) prolongation per se (Jackman et al., 1988; Antzelevitch et al., 1999) . The QTa-e interval was prolonged in a concentration-and reverse ratedependent fashion by both drugs, but was independent of pacing rate in vehicle controls. Moreover, prolongation of the QTa-e interval was associated with a high incidence of torsades de pointes. Thus, this measure might prove to be a useful, quantitative measure of changes in T wave morphology. Further studies are required to assess the sensitivity, speci®city and utility of this measure.
Torsades de pointes occurred commonly after a pause in cardiac activity at low pacing rates and could be precipitated after a pause in cardiac activity during a rate transition at higher pacing rates. Such pause-dependent torsades de pointes might be clinically important (Jackman et al., 1988) . A pause in cardiac activity could occur after a premature beat or may also occur in patients with sinus node dysfunction. Patients converted from atrial ®brillation are known to have sinus node dysfunction and antiarrhythmic drugs can exacerbate this dysfunction. In addition, conversion of atrial ®brillation is associated with sudden changes in ventricular rate. It is not surprising, therefore, that torsades de pointes can occur quickly after conversion of atrial ®brillation to sinus rhythm with Class III drugs (e.g., Kowey et al., 1996; Frost et al., 1997) . The model described in the present study oers the advantage of allowing such pausedependence to be examined.
